Brooklyn Fundamentals
BTX  Stock  USD 0.57 0.01 1.79% 
Brooklyn Immunotherapeutics fundamentals help investors to digest information that contributes to Brooklyn Immunotherapeuti's financial success or failures. It also enables traders to predict the movement of Brooklyn Stock. The fundamental analysis module provides a way to measure Brooklyn Immunotherapeuti's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brooklyn Immunotherapeuti stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Brooklyn  Select Account or Indicator 
Brooklyn Z Score Analysis
Brooklyn Immunotherapeuti's ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2021  2022 (projected)  
Receivables  4.6 K  4.72 K 
Inventories  900  923.68 
Z Score  =  Sum Of   5 Factors 
Current Brooklyn Immunotherapeuti Z Score  11.0 
Most of Brooklyn Immunotherapeuti's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brooklyn Immunotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
In accordance with the company's disclosures, Brooklyn Immunotherapeutics has a Z Score of 11.0. This is 62.96% higher than that of the Healthcare sector and 229.34% higher than that of the Biotechnology industry. The z score for all United States stocks is 26.15% lower than that of the firm.
Brooklyn Immunotherapeuti Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Brooklyn Immunotherapeuti's current stock value. Our valuation model uses many indicators to compare Brooklyn Immunotherapeuti value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Brooklyn Immunotherapeuti competition to find correlations between indicators driving Brooklyn Immunotherapeuti's intrinsic value. More Info.Brooklyn Immunotherapeutics is number one stock in gross profit category among related companies. It is number one stock in z score category among related companies . The ratio of Gross Profit to Z Score for Brooklyn Immunotherapeutics is about 426,364 . Brooklyn Immunotherapeuti Gross Profit is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Gross Profit of 11.09 Million in 2021. Comparative valuation analysis is a catchall model that can be used if you cannot value Brooklyn Immunotherapeuti by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Brooklyn Immunotherapeuti's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the pricetoearnings (P/E), pricetobook (P/B), pricetosales (P/S), pricetocash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Brooklyn Immunotherapeuti's earnings, one of the primary drivers of an investment's value.Brooklyn Immunotherapeuti Current Valuation Drivers
We derive many important indicators used in calculating different scores of Brooklyn Immunotherapeuti from analyzing Brooklyn Immunotherapeuti's financial statements. These drivers represent accounts that assess Brooklyn Immunotherapeuti's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brooklyn Immunotherapeuti's important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  (210.27 K)  (582.15 K)  (212.89 K)  (374.41 K)  (430.57 K)  (464.56 K)  
Revenue Per Employee  36.4 K  63.14 K  63.91 K  33.11 K  38.08 K  52.38 K  
Average Assets  17.55 M  15.62 M  15.29 M  8.94 M  39.08 M  42.17 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  1.8 M  2.83 M  1.4 M  (7.19 M)  (122.02 M)  (125.23 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  1.8 M  2.83 M  1.4 M  (7.19 M)  (122.02 M)  (125.23 M)  
Earnings before Tax  (1.01 M)  (323 K)  (2.02 M)  (7.29 M)  (122.48 M)  (125.7 M)  
Average Equity  5.86 M  6.39 M  6.2 M  3.48 M  17.33 M  18.69 M  
Enterprise Value  11.7 M  6.81 M  10.23 M  8.31 M  195.87 M  211.33 M  
Free Cash Flow  (903 K)  (214 K)  1.65 M  (8.14 M)  (23.64 M)  (24.26 M)  
Invested Capital  5.39 M  9.38 M  8.24 M  9.01 M  11.54 M  10.79 M  
Invested Capital Average  5.34 M  8.47 M  11.74 M  5.55 M  10.2 M  9.61 M  
Market Capitalization  10.61 M  5.6 M  6.38 M  6.64 M  217.02 M  234.16 M  
Tangible Asset Value  14.11 M  12.18 M  11.51 M  10.86 M  29.48 M  23.71 M  
Working Capital  (1.11 M)  2.76 M  (25 K)  (1.39 M)  15.09 M  16.28 M 
Brooklyn Fundamentals
Return On Asset  (65.25) %  
Current Valuation  5.68 M  
Shares Outstanding  52.04 M  
Shares Owned by Insiders  26.39 %  
Shares Owned by Institutions  32.65 %  
Number of Shares Shorted  2.23 M  
Price to Earning  3.97 X  
Price to Book  2.06 X  
Price to Sales  39.92 X  
Revenue  3.45 M  
Gross Profit  4.69 M  
EBITDA  (29.14 M)  
Net Income  (113.41 M)  
Cash and Equivalents  23.5 M  
Cash per Share  0.41 X  
Total Debt  1.17 M  
Debt to Equity  0.07 %  
Current Ratio  6.82 X  
Book Value Per Share  0.25 X  
Cash Flow from Operations  (25.49 M)  
Short Ratio  3.06 X  
Earnings Per Share  (0.45) X  
Price to Earnings To Growth  (0.05) X  
Number of Employees  10  
Beta  3.15  
Market Capitalization  26.93 M  
Total Asset  94.66 M  
Retained Earnings  (241.87 M)  
Working Capital  34.77 M  
Current Asset  47.24 M  
Current Liabilities  12.46 M  
Z Score  11.0  
Last Dividend Paid  0.1 
About Brooklyn Immunotherapeuti Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brooklyn Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brooklyn Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brooklyn Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported  Projected for 2022  
Deferred Revenue  531.3 K  545.3 K 
Cost of Revenue  8.6 M  9.2 M 
Revenues  17.8 M  19.2 M 
Revenue to Assets  0.0195  0.02 
Revenue Per Employee  38.1 K  52.4 K 
Be your own money manager
Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets 
All Next  Launch Module 
Pair Trading with Brooklyn Immunotherapeuti
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Continue to Brooklyn Immunotherapeuti Piotroski F Score and Brooklyn Immunotherapeuti Altman Z Score analysis. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Brooklyn Stock analysis
When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Transaction HistoryView history of all your transactions and understand their impact on performance  Go  
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency  Go  
Efficient FrontierPlot and analyze your portfolio and positions against riskreturn landscape of the market.  Go  
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk  Go  
Price TransformationUse Price Transformation models to analyze depth of different equity instruments across global markets  Go  
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios  Go  
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and riskadjusted market performance  Go  
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges  Go  
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk  Go 
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 32.6 M  Return On Assets 0.65  Return On Equity 17.6 
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.